Japan Medical Device Approval Pmda Consultant

Scope and evidence must be confirmed before any paid tests or filings.

A Japan medical device approval PMDA consultant should resolve the regulatory route before a manufacturer commissions Japan-specific testing or prepares a submission. The first deliverable is a reasoned decision, not an assurance that a PMDA approval is required for every device.

Japan distinguishes notification, certification by a registered certification body, and ministerial approval supported by PMDA review. The correct outcome depends on the product's intended use, Japanese device category and applicable certification standard, as well as the local responsible party and evidence.

Decide whether the product is a Japanese medical device

Do not infer Japanese status from an EU CE mark, a US FDA classification, a distributor's description or the presence of sensors. MHLW decides device-status questions; PMDA says it does not formally determine whether an individual product is a device. An unresolved borderline case should be directed through the appropriate Japanese MAH to the competent local authority or MHLW.

Freeze the exact intended purpose, clinical claims, indications, users and patient population; a broader claim can change the regulatory analysis.
Describe how the product works, its accessories and variants, and whether software makes a medical claim; a low-risk software function may require a separate applicability analysis.
Compare the proposed Japanese generic device name (JMDN), definition and risk class with actual features; do not select a class solely by analogy with an overseas product.

Route matrix: risk class does not decide everything

This is a strategic screening matrix, not a product-specific classification ruling. For Class II and certain Class III devices, verify that a current certification standard actually covers the complete product and its claimed use.

Japanese class	Decision condition	Likely regulatory route and next check
Class I	Class I: general medical device; confirm the Japanese generic-name definition.	Notification to PMDA through an appropriately licensed Japanese MAH; confirm site and product prerequisites before notification.
Class II	Class II: a certification standard applies and all conditions are met; otherwise it does not.	Registered certification body if covered; otherwise MHLW approval following PMDA review. Record the exact standard and exclusions.
Class III	Class III: a certification standard applies to the device and claims; otherwise it does not.	Registered certification body only where covered; otherwise MHLW approval following PMDA review. Do not assume all Class III devices have the same route.
Class IV	Class IV: highest risk category.	MHLW approval following PMDA review; define the evidence and consultation strategy case by case.

The regulator roles differ: MHLW makes ministerial approval decisions, PMDA performs scientific review, and registered certification bodies handle eligible certification cases. The term “PMDA approval” should not obscure those distinctions.

Four-gate gap analysis before committing a budget

Treat each unresolved gate as a documented decision risk. The consultant's work product should state the evidence examined, the proposed route, the open questions and who can settle them.

Decision gate	Minimum facts or documents to examine	Consequence if the gate remains open
Device status and JMDN	Intended-use statement, Japanese claims, technical description, candidate JMDN code and comparison to its definition.	Wrong device category or risk class can invalidate the entire route and planned tests.
Certification eligibility	Current certification standard, product scope, performance specifications and any excluded indication or configuration.	Class II or III may require PMDA review rather than third-party certification despite the risk class.
Japanese responsibility and site status	Proposed licensed MAH or applicable designated structure; manufacturing and quality-system site map; relevant foreign manufacturer registrations.	A manufacturer may have technical evidence but no operationally viable Japanese submission pathway.
Evidence fit and changes	Risk management, performance and clinical rationale, QMS records, existing reports, software version and planned design/claim changes.	Premature testing can target the wrong configuration; later changes may require reassessment.

Reuse foreign evidence, but map its limits

Existing EU, US or international evidence can reduce duplicated work only after a Japan-specific relevance assessment. Neither a CE mark nor an FDA clearance is an automatic substitute for the Japanese market procedure.

Map each test report to the proposed Japanese intended use, device version, applicable standard, acceptance criteria and any gaps; record whether translation or supplementary work is needed.
Compare ISO 13485 documentation with Japan's MHLW Ordinance No. 169 rather than assuming an ISO certificate alone proves every Japanese QMS requirement.
Assess foreign clinical data and literature for the actual indication, population, technology and endpoints; request an appropriate PMDA consultation if acceptability remains material and uncertain.

Use a reuse / bridge / new-evidence decision for each evidence item, with an accountable reviewer. A gap is a question to resolve, not automatic proof that a new Japanese clinical trial is required.

Sequence the strategic decisions before testing or filing

Confirm medical-device applicability, intended use, product boundaries and a defensible JMDN candidate.
Check the risk class and the precise scope of any registered-certification-body standard.
Agree the Japanese MAH and manufacturing-site responsibility map; verify registrations and quality arrangements relevant to the selected route.
Build an evidence-to-claim gap register and distinguish reusable, bridging and genuinely missing data.
Resolve material uncertainty with the competent authority or suitable PMDA consultation before finalizing the test plan, submission owner and filing budget.

This advisory sequence stops at the route decision and evidence plan. For application preparation and submission execution, use the linked service pages rather than treating this article as a filing checklist.

Choose the correct authority for the unresolved question

A PMDA scientific consultation can be appropriate for case-specific evidence, clinical study design or a proposed approval data package; PMDA provides formal paid consultations and preparatory meeting options. Do not book one merely to obtain an informal product-class guess.

Device-versus-non-device boundary: raise the documented intended-use question via a Japanese MAH with the competent prefectural authority or MHLW, consistent with PMDA's published FAQ.
Scientific package for the approval route: prepare a sharply framed PMDA question, supporting alternatives and the decision that will change depending on the answer.

Application forms are in Japanese according to PMDA's FAQ. Verify current consultation categories, eligibility and fees directly before scheduling; no fixed price or review duration is promised here.

What a useful consultant handoff contains

Before authorizing paid testing or filing, request a concise, traceable decision memo rather than a generic “Japan registration required” opinion.

One proposed JMDN classification with evidence, competing interpretations and any question needing authority confirmation.
A route recommendation tied to the exact certification-standard scope, local party/site responsibilities and product claims.
An evidence gap register listing reuse decisions, change triggers, owners and the next controlled action.

Primary official resources

Frequently asked strategic questions

Does every Japan medical device need “PMDA approval”?

No. Class I generally uses notification; qualifying Class II and certain Class III devices use registered-body certification; other Class II/III and Class IV devices require MHLW approval with PMDA review. Confirm the Japanese product classification and applicable standards first.

Can a Class II device automatically use third-party certification?

No. The applicable certification standard must cover the actual device and claims. If coverage is absent, the approval route may apply despite Class II classification.

Can an EU CE certificate or US clearance replace Japanese evidence?

Not automatically. Assess report scope, tested configuration, Japanese claims, local standards and QMS differences. Reuse may be possible; unresolved gaps may call for bridging or new evidence.

Can the overseas manufacturer submit directly without a Japanese partner?

Do not assume so. PMDA describes procedures through a Japanese MAH or relevant appointed Japanese structure. Confirm the applicant/authorization model and manufacturing registrations for the exact product route.

Who decides whether borderline software is a medical device?

PMDA states it does not make formal product-by-product device-status determinations. Prepare intended-use and function details and seek the appropriate MHLW or prefectural-authority determination through the Japanese responsible party.